Literature DB >> 33333017

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD.

Graeme Hewitt1, Valerie Borel1, Sandra Segura-Bayona1, Tohru Takaki1, Phil Ruis1, Roberto Bellelli1, Laura C Lehmann2, Lucia Sommerova3, Aleksandra Vancevska1, Antonia Tomas-Loba4, Kang Zhu5, Christopher Cooper5, Kasper Fugger1, Harshil Patel1, Robert Goldstone1, Deborah Schneider-Luftman1, Ellie Herbert1, Gordon Stamp1, Rachel Brough6, Stephen Pettitt6, Christopher J Lord6, Stephen C West1, Ivan Ahel5, Dragana Ahel5, J Ross Chapman3, Sebastian Deindl2, Simon J Boulton7.   

Abstract

Chromatin is a barrier to efficient DNA repair, as it hinders access and processing of certain DNA lesions. ALC1/CHD1L is a nucleosome-remodeling enzyme that responds to DNA damage, but its precise function in DNA repair remains unknown. Here we report that loss of ALC1 confers sensitivity to PARP inhibitors, methyl-methanesulfonate, and uracil misincorporation, which reflects the need to remodel nucleosomes following base excision by DNA glycosylases but prior to handover to APEX1. Using CRISPR screens, we establish that ALC1 loss is synthetic lethal with homologous recombination deficiency (HRD), which we attribute to chromosome instability caused by unrepaired DNA gaps at replication forks. In the absence of ALC1 or APEX1, incomplete processing of BER intermediates results in post-replicative DNA gaps and a critical dependence on HR for repair. Hence, targeting ALC1 alone or as a PARP inhibitor sensitizer could be employed to augment existing therapeutic strategies for HRD cancers.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALC1; BRCAs; DNA damage repair; DNA gycosylases; PARPs; base excsion repair; chromatin remodeler; homologous recombination defieciency; poly(ADP)-ribosylation; synthetic lethality

Year:  2020        PMID: 33333017     DOI: 10.1016/j.molcel.2020.12.006

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  30 in total

Review 1.  PARP1-modulated chromatin remodeling is a new target for cancer treatment.

Authors:  Saptarshi Sinha; Sefinew Molla; Chanakya Nath Kundu
Journal:  Med Oncol       Date:  2021-08-25       Impact factor: 3.064

2.  Multiple roles for PARP1 in ALC1-dependent nucleosome remodeling.

Authors:  Soon-Keat Ooi; Shigeo Sato; Chieri Tomomori-Sato; Ying Zhang; Zhihui Wen; Charles A S Banks; Michael P Washburn; Jay R Unruh; Laurence Florens; Ronald C Conaway; Joan W Conaway
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-07       Impact factor: 11.205

3.  Critical DNA damaging pathways in tumorigenesis.

Authors:  Jake A Kloeber; Zhenkun Lou
Journal:  Semin Cancer Biol       Date:  2021-04-24       Impact factor: 15.707

Review 4.  Exploiting DNA Endonucleases to Advance Mechanisms of DNA Repair.

Authors:  Marlo K Thompson; Robert W Sobol; Aishwarya Prakash
Journal:  Biology (Basel)       Date:  2021-06-14

Review 5.  Communication between chromatin and homologous recombination.

Authors:  Priyanka Verma; Roger A Greenberg
Journal:  Curr Opin Genet Dev       Date:  2021-06-05       Impact factor: 5.578

Review 6.  CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery.

Authors:  Emily M Schleicher; George-Lucian Moldovan
Journal:  FEBS J       Date:  2021-10-03       Impact factor: 5.542

Review 7.  Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics.

Authors:  Samuel B Hayward; Alberto Ciccia
Journal:  Curr Opin Genet Dev       Date:  2021-09-25       Impact factor: 5.578

8.  REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps.

Authors:  Angelo Taglialatela; Giuseppe Leuzzi; Vincenzo Sannino; Raquel Cuella-Martin; Jen-Wei Huang; Foon Wu-Baer; Richard Baer; Vincenzo Costanzo; Alberto Ciccia
Journal:  Mol Cell       Date:  2021-09-10       Impact factor: 19.328

Review 9.  PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.

Authors:  Lotte van Beek; Éilís McClay; Saleha Patel; Marianne Schimpl; Laura Spagnolo; Taiana Maia de Oliveira
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

10.  Serine-linked PARP1 auto-modification controls PARP inhibitor response.

Authors:  Evgeniia Prokhorova; Florian Zobel; Rebecca Smith; Siham Zentout; Ian Gibbs-Seymour; Kira Schützenhofer; Alessandra Peters; Joséphine Groslambert; Valentina Zorzini; Thomas Agnew; John Brognard; Michael L Nielsen; Dragana Ahel; Sébastien Huet; Marcin J Suskiewicz; Ivan Ahel
Journal:  Nat Commun       Date:  2021-07-01       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.